WO2008104186A1 - Composition pharmaceutique comprenant un stéroïde et des vitamines - Google Patents
Composition pharmaceutique comprenant un stéroïde et des vitamines Download PDFInfo
- Publication number
- WO2008104186A1 WO2008104186A1 PCT/EG2007/000006 EG2007000006W WO2008104186A1 WO 2008104186 A1 WO2008104186 A1 WO 2008104186A1 EG 2007000006 W EG2007000006 W EG 2007000006W WO 2008104186 A1 WO2008104186 A1 WO 2008104186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cortisone
- vit
- treatment
- vitamin
- important
- Prior art date
Links
- 229940088594 vitamin Drugs 0.000 title description 16
- 229930003231 vitamin Natural products 0.000 title description 16
- 235000013343 vitamin Nutrition 0.000 title description 16
- 239000011782 vitamin Substances 0.000 title description 16
- 150000003431 steroids Chemical class 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims abstract description 138
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims abstract description 138
- 229960004544 cortisone Drugs 0.000 claims abstract description 138
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims abstract description 137
- 238000011282 treatment Methods 0.000 claims abstract description 56
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 37
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 37
- 239000011719 vitamin A Substances 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 30
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 14
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 6
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 6
- 239000011710 vitamin D Substances 0.000 claims abstract description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 41
- 239000011701 zinc Substances 0.000 claims description 41
- 235000016804 zinc Nutrition 0.000 claims description 41
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 39
- 239000011591 potassium Substances 0.000 claims description 37
- 229910052700 potassium Inorganic materials 0.000 claims description 37
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 36
- 235000019154 vitamin C Nutrition 0.000 claims description 31
- 239000011718 vitamin C Substances 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 239000011575 calcium Substances 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 20
- 230000001681 protective effect Effects 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 229940047926 potassium 80 mg Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 17
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 11
- 229940045997 vitamin a Drugs 0.000 abstract description 11
- 230000007774 longterm Effects 0.000 abstract description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract description 6
- 229930003571 Vitamin B5 Natural products 0.000 abstract description 6
- 229960002079 calcium pantothenate Drugs 0.000 abstract description 6
- 235000009492 vitamin B5 Nutrition 0.000 abstract description 6
- 239000011675 vitamin B5 Substances 0.000 abstract description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 4
- 229940046008 vitamin d Drugs 0.000 abstract description 4
- 230000003236 psychic effect Effects 0.000 abstract description 3
- 229940045999 vitamin b 12 Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 32
- 229940088597 hormone Drugs 0.000 description 32
- 239000005556 hormone Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 210000004907 gland Anatomy 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 230000006870 function Effects 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- 238000005755 formation reaction Methods 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 210000001508 eye Anatomy 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 22
- 230000006378 damage Effects 0.000 description 20
- 210000000987 immune system Anatomy 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 20
- 230000028327 secretion Effects 0.000 description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 16
- 206010029216 Nervousness Diseases 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 13
- 230000003078 antioxidant effect Effects 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 210000001685 thyroid gland Anatomy 0.000 description 13
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 208000002874 Acne Vulgaris Diseases 0.000 description 9
- 206010000496 acne Diseases 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 206010062767 Hypophysitis Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 238000011866 long-term treatment Methods 0.000 description 8
- 230000036651 mood Effects 0.000 description 8
- 210000003635 pituitary gland Anatomy 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 8
- 239000011726 vitamin B6 Substances 0.000 description 8
- 235000019158 vitamin B6 Nutrition 0.000 description 8
- 229940011671 vitamin b6 Drugs 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229940076279 serotonin Drugs 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 235000019156 vitamin B Nutrition 0.000 description 7
- 239000011720 vitamin B Substances 0.000 description 7
- 208000013016 Hypoglycemia Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 229930003270 Vitamin B Natural products 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 235000020776 essential amino acid Nutrition 0.000 description 6
- 239000003797 essential amino acid Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 208000010428 Muscle Weakness Diseases 0.000 description 5
- 206010028372 Muscular weakness Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 230000007096 poisonous effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010034912 Phobia Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000020825 overweight Nutrition 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 208000019899 phobic disease Diseases 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical group NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000016222 Pancreatic disease Diseases 0.000 description 3
- 206010043268 Tension Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000029422 Hypernatremia Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017826 Gastric ulcer haemorrhage Diseases 0.000 description 1
- 206010017835 Gastric ulcer perforation Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000003306 cortisone group Chemical group 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Definitions
- Cortisone Phobia has been established between the peoples since associated with complications and side effects . Regardless kind of ingredients or results of usage, the patients, who have suffered from such complications, are main example and evidence for harm caused by cortisone. Therefore no one desires to complain of such complications.
- cortisone ingredients are a must, even in some cases if it leads to complications known to- the physicians , because significance and seriousness of the disease is more dangerous than cortisone complications.
- I will stress on complications resulted from using cortisone led to frighten deputation and phobia of using cortisone and answering question like, what is Cortisone? , how and when to cause complications? Does it lead to fibrosis of kidney and hepatocirrhois? Does it cause cancer?
- cortisone has excellent therapeutic effects as well as side effects, which may be, sometimes, dangerous if the patient does not keep with the followed instructions.
- side effects appear when using cortisone excessively by mouth, injection or overdoses for long term which lead to stop normal excretion of cortisone of suprarenal gland . this gland needs weeks or months to resume its work.
- CJ as the following, Raising of eye pressure, cataract which is a layer over person's eyes that prevent him from seeing properly, hyperglycemia, rheumatoid, dysfunction of immunity, circularity of face, increasing of thirsty and urination, pains in the muscles and bones, restrain of sodium in the body which leads to increasing the liquids and establishing edema as well hypertension increasing burden on the heart. Cortisone expels potassium in the urine which leads to heart failure.
- Cortisone also, causes disorder in menstruation, reduces immunity delaying of healing formation the wounds, forms microbes, fungal, obesity resulted from gathering of the fats in the fatty areas, osteopsathyrosis, depression, insomnia, moody tempered, feeble resistance for inflammatory diseases, and influencing liver.
- cortisone lowers immunity; delays wound healing and enhances bacterial, fungal & viral multiplying.
- the immune system fights organisms causing disease is the chief of healing and cure operations and the most well known symptoms of immune system deterioration are:
- the immune system is a system of complicated interactions including different group of organs and substances as - white blood cells ⁇ - bone marrow - lymph vessels and - specialized cells called plasma factors
- the thymus gland is considered the main gland of immune system and there are many factors may cause defect in immune system's work.
- cortisone drugs form an overload on the immune system leading to decrease in the ability of wound healing and lowered immunity against infections.
- Vitamin A which is essential for immune functions and against infection.
- Vitamin C is most important vitamin for immune system and it's of the basics for supra-renal gland hormones production, lymph cells production and has a direct effect on bacteria and viruses.
- ⁇ Cortisone also destroys vitamin C which acts as a primary anti-oxidant and a strong eliminator of poisonous free radicals. Also it reacts in coordination with vitamins E & A to prophylactic against cancer, protects against blood clotting and ecchymosis. ⁇ Vitamin C is also important in collagen formation which protects from skin cracking and helps in production of anti-depression hormones.
- Zinc is important for immune system, supports immune response, and helps in wound healing, prophylactic against acne, so we found people administrating cortisone suffer from acne especially in frontal area of face.
- the body needs vitamin B5 during administration of cortisone.
- This vitamin is vital for steroids production in supra - renal gland, plays an important role in anti-biotic formation, helps the use of other vitamins and it's one of the most powerful vitamins against depression and anti-bodies formation.
- cortisone drugs Some people who have treated by cortisone suffer from over weight and functional insufficiency in some gland due to long term treatment by cortisone drugs.
- ⁇ VIT.B6 is an anti - tension needed by suprarenal gland where insulin secretion is affected by function of supra- renal gland as it secretes adrenaline (epinephrine) which stops insulin secretion, so if there is any disturbance or exhaustion of suprarenal, this may lead to insulin over secretion which leads in turn to hypoglycemia, great desire to eat, especially sweet foods and ends in over weight.
- adrenaline epinephrine
- Zinc activates protein formation, anti-oxidant, immunity supportive and protects all body cells from being destroyed by frees radicals. Thyroid gland is affected also but lack of vits.A and c and the decreased gland hormone leads to over weight.
- ⁇ Vit B complex keeps body glands and cells healthy and help in hormones secretion and activation of enzymes.
- thyroxin stimulating hormone TSH
- ⁇ Tyrosine has an effect on supra-renal, thyroid and pituitary functions.
- Vit.C comes as a very important factor far activity of above mentioned glands where its normal secretion is important for healthy regular menstruation and it is decreased during treatment by cortisone
- ⁇ Vit.C is essential for supra-renal hormones formation and for pituitary gland to keep normal functions of thyroid in turn.
- Vit.B5 plays an important role in supra - renal gland hormones production and helps in use of vitamins and its metabolism. Also considered anti-tension because tension increase elimination of some vitamins and minerals needed by the body to do its function in healthy and right manner.
- Vit.B ⁇ essential for absorption of essential amino-acids required for healthy suprarenal, thyroid and pituitary glands as all these glands as we mentioned before affect regular menstruation. Also vit.B ⁇ shares in keeping immune system health to do its functions and production of anti-bodies.
- ⁇ Zinc is decreased much during treatment by cortisone.
- ⁇ Zinc is needed by the body for protein production which is needed by glands to do its functions in a healthy manner as we mentioned before, also helps to keep cells healthy away from free radicals and supports immune system.
- cortisone leads to some dizziness due to loosing some elements which lead to some troubles in central nervous system accompanied by nausea. And this may be due to lack of vitamin B6 which is essential for:
- Vitamin C improves blood circulation & brain efficiency.
- ⁇ Adding Folic acid is essential for producing red blood cells which carry oxygen.
- hypotension & hypoglycemia resulting from supra-renal function deterioration in some people who are being treated with cortisone may lead to feeling of dizziness & nausea.
- ⁇ Headache occurs in people who are taking cortisone due to lack of chemical substance in brain which is called serotonin which is decreased due to lack of folic acid & vitamin B6 because serotonin consists of these elements which when decreased leads to chemical imbalance in the brain.
- ⁇ Serotonin is a chemical substance in the brain which is decreased during headache and this leads to generation of electrical impulses in Trigeminal nerve affecting blood vessels in meningeal membranes which cover brain from outside leading to inflammation & edema of these vessels causing headache.
- ⁇ Vit. A is needed in the body and it is decreed during treatment by cortisone with and that lads to skin disorders
- ⁇ Vit.A strengthens and protects skin tissues and important for healing and new skin tissue formation.
- cortisone Treatment by cortisone leads to fragile skin and different skin disorders mentioned in leaflet of cortisone drug package, also as shown in the attached photos of my son who is treated by cortisone.
- Vit. C decreased so much due to treatment by cortisone as it's essential for collagen formation which is a protein gives the skin its normal elasticity and important for glands functions like thyroid gland where its disorders lead to skin disorders. Also fights free radicals, reinforces blood capillaries supplying the skin and activates wound and burns healing.
- Vit. C is important also for glands functions like suprarenal gland and lack of vit.C where it causes fragility and minute bleeding beneath the skin (as shown in photos) also lack of vit.C leads to blue discoloration of the skin because these individuals have weaker blood vessels.
- the body needs zinc during treatment by cortisone because it helps in production and formation of protein and collagen, important for regular functions of oil secreting skin glands, protects tissues and repairs it.
- Vit. D helps in thyroid gland function where thyroid gland disorders lead to skin disorders and change in thickness of the skin also lack of vit.D leads to aging of the skin.
- Cortisone may lead especially with long term use to hyper secretion of gastric acid (HcI) leading to inflammations and stomach ulcers. Also Cortisone affects absorption of vitamin B essential for secretion of enough amount of mucus which protects the stomach wall and in this case inner layer of gastric wall isn't protected against increased gastric acid.
- HcI gastric acid
- Cortisone affects absorption of vitamin B essential for secretion of enough amount of mucus which protects the stomach wall and in this case inner layer of gastric wall isn't protected against increased gastric acid.
- ⁇ Vit.B6 is essential for production of hydrochloric acid, enzymes and helps wound healing.
- ⁇ Vit.B6 helps in treatment of allergy and it is lost during treatment by cortisone.
- Vit.C protects from allergens, decreases inflammatory response, activates anti-vital protein (interferon) in the body and its anti-oxidant and reinforces immunity system, and this vitamin is decreased in the body due to treatment by cortisone.
- the body needs vit.A for healthy immune functions and this vitamin is decreased during treatment by cortisone.
- Methonin is one of the essential amino-acid preferred to be obtained through supplement to replace decrease during and from other side to treat side effects resulting from cortisone of which: allergy for chemical substance and lowers histamine in the body. Also it's powerful antioxidant good source for sulfur which resists free radicals, important for elimination of poisoning effects of harmful elements and protect the body from destructive effects of poisonous compounds.
- This disease has many causes of them: aging, diabetes, poisoning with . heavy metals, exposure to irradiation or use of medications like cortisone and mostly due to harm resulting from free radicals which attacks proteins enzymes and cellular membrane of lenses.
- Vitamin C which is lost with cortisone treatment is essential to destroy free radicals and for lowering elevated intra-ocular pressure resulting from cataract, also zinc protects from damage due to exposure to light.
- Cortisone also effects the suprarenal cortex like dixamethasone, Decadrone,hydrocortisone , bredensalone and Bredensone may lead to some eye troubles or cause harm for optic nerve, retina or other vital parts of the eye.
- Vitamin A is important in all eye troubles and the body needs it especially during cortisone therapy.
- ⁇ Potassium is essential for edema relief and sodium, and they keep water balance in the body which is important for chemical reactions, keeping constant blood pressure, electrochemical impulses transmission through the body and its lack leads to acne, weak nervous reflexes, body edema, glucose intolerance, easy fatigue, and muscle weakness, headache in a cyclic manner and sodium retention in tissues. All these symptoms appear in people treated with steroids.
- calcium is essential for strong bone formation, keeping regular heart rate, nervous impulses transmission, essential for muscle growth and contraction, prevents loss of osteagenic substance which leads to osteoporosis.
- ⁇ calcium lack leads to joint pain, hypertension, nervous spasm, nervous mood, rheumatic arthritis, deterioration in sensual abilities, depression, convulsions, and psychic and nervous irritability.
- Vitamin B6 which is decreased by cortisone helps in keeping the sodium and potassium balance and its lack leads to arthritis.
- Vitamin B6 increase fat and carbohydrates assimilation in muscles and acts as a light diuretic.
- Vitamin C which is decreased by cortisone and it is essential for muscle, bone and tissue repair. And it is important for calcium absorption and reduces pain and swelling.
- Vitamin A helps in proteins use which are essential in muscle building and tissues repair.
- ⁇ Cortisone decreases levels of vitamin A, in the body which has many functions in the body as:
- Vitamin A is important in muscle and bone formation because the body cannot use and benefit from protein in absence of vitamin A and it's known that vitamin A is decreased during treatment by cortisone.
- Taurine which is one of unessential amino-acids found in high concentrations in skeletal muscles and central nervous system and it vital for perfect benefits from sodium, potassium, calcium and magnesium. It also plays a special role in limiting loss of potassium from heart muscle.
- ⁇ Taurine is formed in presence of enough amount of vitamin B6 in blood, so patients treated by cortisone have decreased vitamin B6, so it's proffered to be added with cortisone drugs to replace this decrease in to allow it to play its vital functions in the body.
- ⁇ Vit.A which is decreased during treatment with cortisone is considered important in eye disorders, essential in all eye disease, fluid balance in the eye and it's a powerful anti-oxidant.
- Vit.A ,vit.C and Zinc help in immunity reinforcement which is very important in protection of the eyes from diseases and enhances cure.
- ⁇ Vit.C is an important anti-oxidant, essential for removal of free radicals, protects eyes from damage, lowers elevated blood pressure improves blood circulation, helps in wound healing and antiviral.
- ⁇ Diabetes may lead to complications in retina in the form of blood and fluid leak from capillaries supplying retina leading to harm of rods and cones, then new capillaries start to form in affected parts causing difficult vision.
- Glaucoma Because treatment by cortisone leads to loss of most of important elements for cells and eyes health. Glaucoma
- ⁇ Vit.A is important for visual purple formation required for night vision, also it's a strong anti-oxidant and so important in all eye diseases.
- ⁇ Vit.B5 is anti-nervous hypertension and important component for coenzyme A which is important for many of biological assimilation and dietary assimilation inside eye cells.
- Vit.C lowers intra-ocular pressure, anti-oxidant and protects eye cells, and tissues, and vit.C is lost from the body during treatment by cortisone.
- ⁇ Zinc which is lost from the body during treatment by cortisone is important for activation of vit.A from liver and useful in treatment of glaucoma.
- Cortisone drugs may lead to glaucoma through destruction of collagen formations in the eye , so essential elements must be added which is vital for prophylaxis and protection of the eye against glaucoma.
- Cortisone therapy leads to a great lack of some essential elements in the body like vits.C,B6,B5 anc [ zinc,causes negative balance of nitrogen in the body.
- the body needs vit.B6 and Vit.C to activate amino-acids absorption and to create some other amino-acids.
- the body needs also vit.A which helps in use and benefit from proteins converted to amino-acids helping in nitrogen balance in the body like Argenin,Asparthic Acid ,Glutamin,Sitrolin,cystin and Falin.
- Zinc is considered essential for protein production in the body an protection of liver from damage. Also it increases absorption of vit.a and helps in addition to vit. and vit.C to resist free radicals and prevents its formation.
- Amino-acid Methonin is considered a strong anti-oxidant, good source for sulpher which resists free radicals, also important for proteins and amino-acid production in every cell in the body, elimination of poisonous effects of any harmful elements in the body.
- pancreatic cells ⁇ -cells which secrete the hormone which transforms glucose stored in liver and muscles to glucose ready for use when glucose level in blood is lowered, also convert glycogen to glucose.
- pancreatic cells Another type of pancreatic cells is ⁇ -cells which secrete insulin hormone responsible for glucose utilization by the body and without this insulin, glucose will accumulate in blood leading to appearance of different pathologic symptoms.
- ⁇ Also insulin regulates glucose level in blood and its storage in liver.
- Zinc & calcium are considered essential and important to protect from pancreatic troubles, as the body's need to calcium and Zinc is increased during the treatment by cortisone, researches also proved that lack of potassium during treatment by cortisone leads to glucose intolerance because long term use of cortisone affects badly supra-renal functions.
- Potassium leads to glucose intolerance and Potassium is essential for nervous system health, work with Sodium on regulation of body's water balance, important for cellular chemical reactions, regulates food elements passage through cell membrane and lack of Potassium leads to nervous mood, depression, deterioration of mental abilities, thirst, growth retardation, poor neural reflexes, fatigue, muscle weakness and many other symptoms.
- vit.B5 is essential for suprarenal functions, conversion of glucose to energy .Vit.B5 in addition of being anti-tension and essential for thymus gland,it playes also an important role in suprarenal hormones production, anti-bodies formation. And this vit. is a basic element in coenzyme A composition.
- ⁇ Vit.A is required for eye health in diabetic patients, in addition it's antioxidant, helps to protect cells and essential for growth of new cells.
- ⁇ Unessential amino-acids includes an important group for diabetic patients like Tourin as diabetes increases body needs of Tourin which lowers body needs of insulin and help its secretion.
- This amino-acid formation in the body is essential, so it's preferred to administrate vit.B ⁇ to help formation of this amino-acid in the body.
- Vit.B ⁇ which is decreased during use of cortisone helps in protection from heart disease, atherosclerosis, lowers a poisonous chemical substance called hoecyctin which attacks heart muscle causing accumulation of cholesterol in heart muscle. Also vit.B ⁇ helps excretion of excess body fluids.
- ⁇ Potassium is essential for regular heart rate and treatment by cortisone deprives the body from Potassium.
- ⁇ Potassium is essential for cellular chemical reactions, keeping constant blood pressure, transmission of electrochemical impulses through the body and regulates transport of dietetic elements through cell membranes.
- ⁇ Vit.B6 helps in formation of amino-acid Tourin which is found in high concentrations in heart muscle and useful for patients of atherosclerosis, ascites, heart disease or hypertension. Also plays an important role in limiting Potassium loss from heart muscle and helps to prevent serious troubles in heart rate.
- ⁇ Protein is converted to amino-acid which is used in many processes, for example amino-acid Arginin needed by pituitary to release growth hormone, also amino-acid Ornitin activates growth hormone secretion in addition to amino-acid Lycin needed by the body for growth and the correct bone formation in children and Leocin which helps in production of growth hormone.
- Vit.B ⁇ and vit.C help in activation, absorption and creation of these amino-acids. Vit.B ⁇ and vit.C are decreased during treatment by cortisone which affects many of body biological functions including normal growth.
- vit.A which is decreased in the body due to cortisone therapy is required for normal growth of bones and tissues, and body cannot benefits from proteins in absence of vit.A.
- Vit.A shares vit.C in protection of glands cells including pituitary gland which secretes growth hormone, also keep it safe from destruction by free radicals.
- Zinc strengthen immune system and prevents free radical formation, also Zinc increases the absorption of vit.A.
- Depression is one of side effects of the treatment by cortisone drugs.
- the neuro-transmitter; serotonin is formed of the amino-acid Tryptophan with help of Folic Acid and vit.B ⁇
- vit .B6 is anti-depression vitamin
- vit .B5 is the most powerful anti-depression hormone, helps in perfect use of other vitamins and supports suprarenal and thyroid glands functions.
- ⁇ Calcium has a sedative effect, important for nervous system work, transmission of nervous motive and its lack which occurs due to administration of cortisone drugs leads to a nervous mood.
- ⁇ Vit.C is important for suprarenal gland as tension depletes suprarenal hormones and anti-depression hormones.
- ⁇ Potassium is administered to replace the loss of this element during nervous tension and its lack leads to a nervous mood, nervous tension and also has real effects on body.
- the body responds to tension by a chain of physiological reactions including increased adrenaline secretion.
- Tension also affects body parts related to nervous system especially digestive system and if tension isn't handled in a right manner serious problems may occurs as long term nervousness especially is considered dangerous due to its effects on immune system and possibility of being diseased.
- the poisons present in the body may have many reasons, of these reasons increased tension-hormones secretion, free radicals prevalence due to use of some drugs, pollution and others.
- Vit.C eliminates poisons of many harmful substances, playes an important role in immunity and increases, inter-ferone formation which is a naturally an anti-viral substance stimulates activity of some cells.
- Vit.B ⁇ enters in cellular proliferation and it is also decreased during treatment by cortisone.
- ⁇ Vit.A is important to support protective coating tissues and acts as an intermediate anti-inflammatory.
- ⁇ Vit.C activates immune system, relieves inflammation and supports blood capillaries.
- ⁇ Vit.B5 is anti-tension, helps in keeping skin healthy, playes a role in anti-baiotics formation and helps in using other vitamins.
- vits.A ,C and B complex which are essential for suprarenal and pituitary glands health, which fed on these elements and are essential for amino-acids created in the body from these elements ,and any decrease in these lements due to adminstrtion of cortisone drugs may lead to disturbance in these glands which are important for the body.
- the amino acid called Tourin is considered one of unessential amino acids and produced by the body when needed. As long as enough amount of vit.B ⁇ found, this amino-acid can be produced in the body with help of amino-acid cysteine which needs also presence of B6 for its formation in the body.
- ⁇ Tourin is important for right use of sodium, potassium, calcium and magnesium playes an important and special role in limiting loss of potassium from heart muscle, useful in hypertension and ascites and during lack of vit.B ⁇ from the body during treatment by cortisone.
- Vit.B ⁇ is needed in the body for formation of some amino-acids which is turn enable vitamins and minerals to do its functions.
- Vit.B ⁇ decreases fluid accumulation.
- the body needs Zinc for production of proteins important for suprarenal gland safety, also increase activity of vit.A important for safety, health and activity of suprarenal cortex which keeps water and electrolyte balance in the body.
- ⁇ And Potassium is important for chemical reactions in cells, helps in maintaining blood pressure and electrochemical impulses transmission.
- Blood clotting is considered life saving in some situations but in presence of some disorder it may become lethal.
- clotting factors also to proteins which consist these factors and effect of some drugs and substances on these factors and the process itself.
- ⁇ Vit.C keeps blood like liquid, protects from clotting, improves blood circulation, keeps liver healthy because the liver is like a factory inside which blood protein and clotting factor like Fibrinogen, prothrombin, and heparin, which are concerning blood clotting.
- Vit.B complex which decreased during treatment by cortisone is considered very important for digestion and good absorption of proteins and for proteins composition in the body because all hormones and enzymes stimulating and regulating biological processes in the body are proteins in nature. Also vit.B complex considered essential for healthy liver functions and for liver cells reformation.
- ⁇ Vit.A and Zinc help in use and production of proteins because proteins cannot be used without vit.A which is decreased during treatment by cortisone drugs.
- Amino-acids resulting from protein assimilation like Argenin,Ornitin and Glutatheon are essential for liver enzymes and functions.
- vit.A and Zinc are anti-oxidant factors keep liver cells safe from destruction by effect of free radicals.
- Vit.A and Zinc help in protein production and decreased during treatment by cortisone and they are a anti-oxidant protect liver cells from free radicals.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1- Certains patients souffrent de complications dues à un traitement à la cortisone. 2- Identification des causes réelles des complications liées à la cortisone et traitement. 3- Il est nécessaire d'ajouter certains éléments comme substances efficaces aux médicaments à base de cortisone afin d'offrir une protection contre les complications liées à la cortisone. 4-(Corti-safe) est un médicament nouvellement mis au point qui offre une protection contre les maladies causées par un traitement avec des médicaments à base de cortisone. 5- L'invention permet d'alléger la charge psychique et physiologique qui pèse sur les patients traités à la cortisone et la charge financière à laquelle s'expose le gouvernement en cas de complications dangereuses liées à la cortisone. 6- L'invention permet de protéger les patients de maladies dangereuses entraînées par la prise de cortisone à long terme et de rendre le médicament sans danger pour tout patient qui a besoin d'un tel traitement. 7- Selon l'invention, afin d'offrir une protection contre les effets secondaires liés la cortisone, on ajoute aux médicaments à base de cortisone du calcium, du potassium, du zinc, de la vitamine B5, de la vitamine B6, de la vitamine B12, de la vitamine A, de l'acide folique, de la vitamine D et de la L-Méthonine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EG2007/000006 WO2008104186A1 (fr) | 2007-02-28 | 2007-02-28 | Composition pharmaceutique comprenant un stéroïde et des vitamines |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EG2007/000006 WO2008104186A1 (fr) | 2007-02-28 | 2007-02-28 | Composition pharmaceutique comprenant un stéroïde et des vitamines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008104186A1 true WO2008104186A1 (fr) | 2008-09-04 |
Family
ID=39720857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EG2007/000006 WO2008104186A1 (fr) | 2007-02-28 | 2007-02-28 | Composition pharmaceutique comprenant un stéroïde et des vitamines |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008104186A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010131038A3 (fr) * | 2009-05-13 | 2011-01-06 | Isis Innovation Limited | Composition contenant un stéroïde et ses utilisations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639585A (en) * | 1968-03-29 | 1972-02-01 | Res Inst Medicine Chem | Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method |
WO2004014143A1 (fr) * | 2002-08-13 | 2004-02-19 | Akzo Nobel | Compositions et methode pour administration d'un additif |
US20060270590A1 (en) * | 2005-03-29 | 2006-11-30 | Lockwood Samuel F | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
-
2007
- 2007-02-28 WO PCT/EG2007/000006 patent/WO2008104186A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639585A (en) * | 1968-03-29 | 1972-02-01 | Res Inst Medicine Chem | Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method |
WO2004014143A1 (fr) * | 2002-08-13 | 2004-02-19 | Akzo Nobel | Compositions et methode pour administration d'un additif |
US20060270590A1 (en) * | 2005-03-29 | 2006-11-30 | Lockwood Samuel F | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
Non-Patent Citations (4)
Title |
---|
DATABASE MEDLINE [online] FREQUIN S.T. ET AL.: "Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone", Database accession no. (NLM8326337) * |
DATABASE MEDLINE [online] SAUNDERS R.D. ET AL.: "Effects of methylprednisolone and the combination of alpha-tocopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue", Database accession no. (NLM3108455) * |
JOURNAL OF NEUROCHEMISTRY, vol. 49, no. 1, 1987, pages 24 - 31 * |
JOURNAL OF NEUROLOGY, vol. 240, no. 5, 1993, pages 305 - 308 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010131038A3 (fr) * | 2009-05-13 | 2011-01-06 | Isis Innovation Limited | Composition contenant un stéroïde et ses utilisations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
US7785619B2 (en) | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens | |
WO2016062283A1 (fr) | Applications d'un médicament anti-inflammatoire dans la préparation d'une composition pharmaceutique destinée à inhiber le cancer | |
Eze et al. | Therapeutic effect of honey bee venom | |
RU2014122168A (ru) | Улучшение памяти у пациентов с оценкой 24-26 баллов по краткой шкале оценки психического статуса | |
WO2005102295A1 (fr) | Composition(s) et système(s) de pharmanutrition destinés à des régimes posologiques individualisés adaptés aux besoins | |
US20090082738A1 (en) | Natural Anti-Inflammatory Agents for Reducing Pain | |
Johnstone et al. | Endocrine system: part 1 | |
WO1999003482A1 (fr) | Associations de mineraux et de vitamines destinees au traitement du stress et des allergies | |
Savasky et al. | Nutritional and pharmacological effects on oxidative stress in soft tissue and bone remodeling | |
CA2107078A1 (fr) | Utilisation de la riboflavine dans le traitement de maladies liees aux virus vih, de l'herpes, de la retinite pigmentaire et du paludisme | |
US20040086581A1 (en) | Bio-energetic joint and arthritis pain formula | |
US5639482A (en) | Composition for control and prevention of diabetic retinopathy | |
Naeem et al. | Efficiency of proteolytic enzymes in treating lumbar spine osteoarthritis (low back pain) patients and its effects on liver and kidney enzymes. | |
US9687518B2 (en) | Medicament for treating muscle and skeletal diseases | |
WO2008104186A1 (fr) | Composition pharmaceutique comprenant un stéroïde et des vitamines | |
JP2022507646A (ja) | ブレイアコニチンaの用途 | |
CN1213747C (zh) | 爱滋病特效药 | |
Nefodov et al. | Efficiency of neuroprotections at experimental allergic encephalomyelitis on the background of therapy by methylprednisolone | |
WO2010017403A9 (fr) | Compositions thérapeutiques, dispositifs et procédés pour l'observation de tissus traités | |
US20150320096A1 (en) | Dietary Supplement | |
US20190110512A1 (en) | Food composition for relieving symptoms of viral diseases | |
FR3102058A1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
US20240226046A1 (en) | Composition containing lysine for the treatment of poison ivy, composition containing lysine for the prevention of poison ivy, processes, and method of use | |
RU2709502C1 (ru) | Фармацевтическая композиция для парентерального капельного введения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2008010178 Country of ref document: EG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07702550 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07702550 Country of ref document: EP Kind code of ref document: A1 |